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The aim of the present study was to describe the plasma pharmacokinetic profile and skin 
concentrations of lincomycin after intravenous administration of a 15% solution and oral 
administration  of  300  mg  tablets  at  a  dosing  rate  of  15  mg/kg  to  cats.  Susceptibility  of 
staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also 
determined. Lincomycin plasma and skin concentrations were determined by microbiological 
assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established 
by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration–time 
curves were analysed by a non-compartmental approach. After intravenous administration, 
volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 
0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma 
concentration, time of maximum plasma concentration and bioavailability were 22.52 µg/mL 
± 10.97 µg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin 
administration,  skin  concentrations  were  17.26  µg/mL  ±  1.32  µg/mL  (intravenous)  and 
16.58 µg/mL ± 0.90 µg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 
(intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in 
this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, 
lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, 
with a long elimination half-life and effective skin concentration. Therefore, it could be a good 
first option for treating skin infections in cats.
Introduction 
Lincomycin  is,  as  clindamycin,  a  lincosamide  antibiotic  mainly  active  against  staphylococci, 
streptococci and anaerobic bacteria (Giguère 2006). It is recommended for treating skin and other 
soft tissue infections produced by susceptible bacteria in dogs and cats (Papich & Riviere 2009). 
Lincosamides are antibiotics classified as ‘important’ (instead of ‘critically important’ or ‘highly 
important’)  based  on  their  importance  in  human  medicine  (WHO  2005,  cited  by  Collignon, 
Courvalin & Aidara-Kane 2008) and would therefore be a better alternative to other antibiotics 
for the treatment of bacterial infections in animals (Collignon et al. 2008).
Lincomycin  achieves  therapeutic  concentrations  in  most  body  tissues  (Giguère  2006)  and  is 
widely metabolised in the liver to inactive metabolites that are eliminated through bile and urine 
(Brown et al. 1975; Hornish, Gosline & Nappier 1987).
Lincomycin pharmacokinetics have been studied in calves (Burrows, Barto & Weeks 1986), pigs 
(Kuroha, Son & Shimoda 2001; Nielsen & Gyrd-Hansen 1998), sheep (Ziv & Sulman 1973), goats 
(Abo El-Sooud, Goudah & Abd El-Aty 2004), chickens (Soback et al. 1987) and cats (Albarellos 
et al. 2012). However, to the authors’ knowledge there is no published information on lincomycin 
pharmacokinetic behaviour after oral administration in cats.
The  aim  of  this  study  was  to  characterise  the  plasma  pharmacokinetic  profile  and  skin 
concentrations of lincomycin after intravenous and oral administration in domestic cats.
Materials and methods
Experiment animals
Experimental animals were five adult (5-year-olds) mixed-breed cats, with an average weight 
of 4.95 kg ± 0.55 kg. All cats were healthy, as determined by clinical examination, complete blood 
and plasma biochemical analysis and urinalysis. Animals were housed in facilities at the Faculty 
of Veterinary Medicine, University of Buenos Aires and allowed to acclimatise for two months 
before the experiment. Access to a high-quality commercial dry food (Royal Canin®, Argentina) 
and water was available ad libitum before the study. All animal procedures were approved by 
the Institutional Animal Care and Use Committee, School of Veterinary Science, University of 
Buenos Aires, Argentina. 
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Dosage form
A  15%  lincomycin  aqueous  solution  (Tritonyl  inyectable®, 
Triton  Vet  S.R.L.,  Argentina)  was  used  for  intravenous 
administration.  The  dose  (15  mg/kg)  was  half  diluted 
with saline (NaCl 0.9%) before administration and infused 
over a 3 min period. For the oral administration, marked 
300 mg lincomycin tablets (Tritonyl 300®, Triton Vet S.R.L, 
Argentina)  were  used.  Each  animal  received  75  mg  (each 
tablet was divided into quarters).
Experiment design
The study was carried out in a randomised cross-over design 
with a two week washout period. 
Lincomycin  was  administered  intravenously  (15  mg/kg) 
through  a  24G  catheter  (Abbocath-T,  Venisystems, 
Abbott,  Ireland)  placed  into  the  cephalic  vein.  For  oral 
administration,  a  quarter  tablet  was  administered  per 
cat (actual dose of 15.19 mg/kg ± 1.65 mg/kg). Cats were 
deprived of access to food for 12 h prior to the study and up 
to 6 h post administration.
Blood sampling
For blood collection, a jugular vein was catheterised 24 h 
before  each  study  according  to  a  technique  described 
previously (Albarellos et al. 2003). 
The same blood sampling schedule was used for both phases 
of the study. Blood samples (0.7 mL) were collected through 
the  jugular  catheter  prior  to  antibiotic  administration  and 
at the following post-administration times: 5 min, 10 min, 
20 min, 30 min, 45 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 
10 h and 12 h.
  
Samples were collected into heparinised tubes, mixed and 
placed on ice until plasma separation 30 min later. Plasma 
was  separated  after  centrifugation  (1500  g,  15  min)  and 
stored at –20 °C until analysis. All samples were assayed in 
the week after collection. 
Skin sampling
Skin  samples  (1  cm2)  were  collected  under  general 
anaesthesia (tiletamine/zolazepam 10 mg/kg, Zelazol, Fort 
Dodge,  Pfizer  S.R.L.,  Argentina)  from  the  loose  skin  over 
the shoulders two hours after lincomycin was administered 
(either intravenously or orally). Samples were rinsed briefly 
with saline solution, dried with sterile gauze, weighed and 
stored at –20 °C.
To  avoid  heat  inactivation  of  the  antibiotic,  skin  samples 
were  carefully  and  slowly  cut  to  small  pieces  (≈1  mm3). 
Lincomycin  was  eluted  using  the  technique  described  by 
Bamberger et al. (2005). Briefly, samples were incubated in 
0.1 m phosphate buffer pH 7.8 (in a ratio 1:2 w/v) for 24 h at 
4 °C, applying agitation during the first 40 min of incubation. 
Samples were subsequently centrifuged (1500 g, 15 min) and 
the supernatant fluid was collected.  
Lincomycin determination
Lincomycin plasma and skin concentrations were determined 
by microbiological assay (Bennet et al. 1966) using Kocuria 
rhizophila  (formerly  Micrococcus  luteus)  ATCC  9341  as  test 
microorganism.  This  method  was  selected  because  of  its 
sensitivity,  simplicity  and  good  correlation  with  high-
performance liquid chromatography (HPLC) determination 
(Strachunskii  et  al.  1993).  Standard  curves  were  prepared, 
depending  on  the  sample  matrix  to  be  quantified,  on 
normal cat plasma or phosphate buffer pH 7.8. Each sample 
was  seeded  in  triplicate  and  each  standard  dilution  in 
quintuplicate.  The  limits  of  detection  and  quantification 
of  the  method  for  plasma  and  phosphate  buffer  were 
0.78 µg/mL and 1.56 µg/mL, respectively. The method was 
linear between 0.78 µg/mL and 50 µg/mL (r = 0.9965). Inter- 
and intra-assay coefficients of variation were less than 10%. 
Pharmacokinetic analysis
Individual  lincomycin  plasma  concentration–time  curves 
were  analysed  by  a  non-compartmental  approach  with 
a  software  programme  (PCNONLIN  4.0,  SCI  Software, 
Lexington,  KY,  USA).  Major  pharmacokinetic  parameters 
were calculated according to classical equations (Gibaldi & 
Perrier 1982). The observed maximum plasma concentration 
(Cmax)  and  time  of  maximum  plasma  concentration  (Tmax) 
were recorded directly from the data. The apparent terminal 
rate constant, kz, was determined by linear regression of the 
last five or six points on the terminal phase of the logarithmic 
plasma concentration–time curves. 
Statistical analysis
The  means  and  standard  deviations  of  pharmacokinetic 
parameters are expressed. Main pharmacokinetic parameters 
(area under the curve [AUC(0-∞)], elimination half-life [T½] and 
mean residence time [MRT]), skin concentrations and skin: 
plasma concentration ratios were compared statistically for 
the  two  administration  routes,  applying  a  nonparametric 
paired  test  (Wilcoxon  test).  Differences  were  considered 
statistically significant at p ≤ 0.05.
Susceptibility test on Staphylococcus spp. and 
Streptococcus spp.
A  total  of  31  Staphylococcus  strains  and  23  Streptococcus 
strains were isolated from skin and mucosal infections from 
clinical cases attending the Small Animals Hospital, Faculty 
of Veterinary Science, University of Buenos Aires.
Bacterial susceptibility to lincomycin was established by an 
antimicrobial  disc  diffusion  test,  using  2  µg  clindamycin 
discs  in  accordance  with  CLSI  (2008)  recommendations. 
Staphylococcus  aureus  ATCC  25923  and  Streptococcus 
pneumoniae ATCC 49619 were used as quality controls. 
Results
No  adverse  effects  were  observed  during  or  following 
administration (either route) of lincomycin in any of the cats.
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The  mean  plasma  concentration–time  curves  for  the  two 
administration  methods  of  the  antibiotic  are  shown  in 
Figure  1.  Estimated  pharmacokinetic  parameters  for  both 
administration routes are summarised in Table 1. 
Oral absorption was rapid (Tmax = 0.80 h ± 0.11 h) although 
quite  variable  between  animals  (Cmax  =  22.52  µg/mL  ± 
10.97 µg/mL). Lincomycin oral bioavailability (F) was almost 
complete (F = 81.78% ± 24.05%). No statistically significant 
differences  were  observed  between  pharmacokinetic 
parameters after intravenous or oral administration. 
Lincomycin skin concentrations are shown in Table 2. For 
both  administration  routes,  the  lincomycin  concentrations 
were higher than the corresponding plasma concentration; 
skin: plasma ratio for intravenous and oral administration 
was 2.08 ± 0.47 and 1.84 ± 0.97, respectively. No statistically 
significant differences were observed in skin concentrations 
or skin: plasma ratios between administration routes.  
Of  the  tested  staphylococci  samples,  87.09%  (27/31)  were 
susceptible to lincomycin, whilst 69.56% (16/23) of the tested 
streptococci samples were susceptible to the antibiotic.
Discussion
Lincomycin is an antibiotic with long duration in the body 
owing to its lipid solubility and wide tissue distribution. It 
has good activity against Gram-positive cocci and anaerobes. 
Because of these features, lincomycin is recommended for the 
treatment of a variety of skin, respiratory, gastrointestinal, 
soft-tissue  and  bone  infections  (Greene  &  Boothe  2012; 
Patel 2006).
The  microbiological  assay  for  measuring  lincomycin 
concentrations  in  plasma  and  other  biological  matrices 
has been used in many studies (Abo El-Sooud et al. 2004; 
Albarellos et al. 2011; Brown et al. 1975; Burrows et al. 1986; 
Marcus,  Ziv  &  Glickman  1995;  Nielsen  &  Gyrd-Hansen 
1998; Soback et al. 1987; Ziv & Sulman 1973). This analytical 
method  is  appropriate  and  accurate  as  lincomycin  has 
no active metabolites (Brown et al. 1975; Brush et al. 1976; 
Hornish et al. 1987).
It  is  important  to  emphasise  that  animals  were 
anaesthetised  for  skin  sampling  for  approximately 
30  min.  Clinical  parameters  were  carefully  monitored 
throughout  the  procedures  and  all  the  cats  remained 
stable,  but  haemodynamic  modifications  influencing  the 
pharmacokinetic behaviour of lincomycin cannot be ruled 
out.  However,  previous  antimicrobial  pharmacokinetic 
studies  performed  in  anaesthetised  dogs,  although  with 
a  different  antibiotic,  showed  no  significant  changes  in 
pharmacokinetic parameters (Duval & Budsberg 1995). 
Lincomycin  pharmacokinetic  parameters  after  intravenous 
administration were similar to those reported in a previous 
study (Albarellos et al. 2012). However, the dose used in the 
present study was higher than the one used in the earlier 
study  by  Albarellos  et  al. (2012).  This  difference  is  clearly 
observed  in  the  dose-dependent  parameters  that  varied 
accordingly. 
Lincomycin oral absorption was rapid and almost complete 
(Tmax = 0.80 h and F = 81.78%). Similar high oral bioavailability 
was  reported  by  Nielsen  and  Gyrd-Hansen  (1998)  after 
lincomycin administration to fasted pigs. 
No  statistically  significant  differences  were  observed 
for  elimination-related  parameters  (T½  and  MRT)  when 
comparing the two administration routes. 
Lincosamides  are  lipophilic  antibiotics  and  are  therefore 
expected to achieve higher concentrations in most tissues than 
in plasma (Giguère 2006). In a study analysing clindamycin 
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FIGURE 1: Mean (± SEM) lincomycin plasma concentration–time profile after 
intravenous and oral administration to cats at a dosing rate of 15 mg/kg (n = 5).
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TABLE  1:  Pharmacokinetic  parameters  (mean  ±  s.d.)  of  lincomycin  after 
intravenous and oral administration to cats at a dosing rate of 15 mg/kg (n = 5).
Pharmacokinetic parameter Intravenous administration Oral administration
Cp(0) (µg/mL) 38.84 ± 6.25 –
AUC(0-∞) (µg.h/mL) 98.47 ± 40.83 97.92 ± 52.37
VD(area) (L/kg) 0.97 ± 0.15 –
Tmax (h) – 0.80 ± 0.11
Cmax (µg/mL) – 22.52 ± 10.97
ClB (L/h.kg) 0.17 ± 0.06 –
T½ (h) 4.20 ± 1.12 4.12 ± 1.44
MRT (h) 5.50 ± 1.64 6.38 ± 2.22
F (%) – 81.78 ± 24.05
Note:  No  statistically  significant  differences  were  observed  between  the  two  routes  of 
administration.
AUC(0-∞), area under the plasma concentration–time curve from 0 to infinity; Cmax, maximum 
concentration; Cp(0), plasma concentration at 0 time; ClB, body clearance; F, bioavailability; 
MRT, mean residence time; Tmax, time of maximum concentration; T½, elimination half-life; 
VD(area), volume of distribution
TABLE 2: Lincomycin plasma and skin concentrations (mean ± s.d.) taken two 
hours after lincomycin administration and skin: plasma concentration ratio after 
intravenous and oral administration (15 mg/kg) to cats (n = 5).
Tissue concentration Intravenous administration  Oral administration
Plasma (µg/mL) 8.60 ± 1.73 11.70 ± 7.18
Skin (µg/g) 17.26 ± 1.32 16.58 ± 0.90
Skin: plasma ratio 2.08 ± 0.47 1.84 ± 0.97Original Research
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tissue concentrations in cats, Brown et al. (1990) found tissue: 
plasma  ratios  >  1.  In  the  present  study  we  found  similar 
results.  Lincomycin  skin  concentrations  were  higher  than 
the corresponding plasma concentrations and skin: plasma 
ratios were also > 1,  reflecting lincomycin accumulation in this 
tissue. However, it was noted that whole tissue concentrations 
are difficult to interpret because they represent the sum of 
all concentrations (intracellular, extracellular fluid and also 
any remaining blood contamination). It is also important to 
note that in the present study skin samples were taken at a 
single time point (2 h after antibiotic administration) and a 
single dose was administered. Therefore, the expected tissue 
accumulation in an ordinary therapeutic treatment could not 
be analysed. 
Lincomycin  skin  concentrations  and  skin:  plasma  ratios 
were equivalent for both administration routes assayed. This 
finding is in accordance with the similar plasma concentration 
profile of the drug for the two administration routes and its 
high oral bioavailability.
Plasma lincomycin concentrations after intravenous or oral 
administration  were  well  above  MIC50  values  recorded  in 
literature (Albarellos et al. 2012; Giguère 2006) for the entire 
proposed dosing interval for this antibiotic (8 h – 12 h) (Plumb 
2011). According to results of this study, a 15 mg/kg oral 
dose of lincomycin could allow a 12 h dosing interval in cats.
Similarly, lincomicyn skin concentrations were above an MIC50 
of 1 µg/mL, but this refers to a single time point. However, it 
is possible to assume that lincomycin accumulates in tissues 
(because of its chemical characteristics) and therefore tissue 
concentrations  will  remain  above  plasma  concentrations 
throughout the dosing interval.
Most of the staphylococci and streptococci samples tested 
in this study were susceptible to lincosamides (87.09% and 
69.56%, respectively); however, it is important to consider 
that lincomycin antibacterial activity could be overestimated 
because  antimicrobial  susceptibility  was  evaluated  with 
clindamycin discs (a more potent lincosamide) (CLSI 2008). 
Nevertheless,  bacterial  susceptibility  rates  for  lincomycin 
found in this study suggest that lincomycin could be a good 
first  option  for  treating  the  majority  of  skin  infections 
in cats. 
Conclusion
According  to  the  data  obtained  in  this  study,  lincomycin 
would  be  a  useful  alternative  for  the  treatment  of 
uncomplicated skin infections in cats.
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